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 The right chance for temozolomide in metastatic colorectal cancer? 
Among big killer cancers, remarkable advances have been achieved in clinical molecular and 
immunological oncology for a large fraction of patients with lung, breast, or prostate cancer, but 
only  for small subsets of patients with colorectal cancer (CRC)[1]. In the latter histology, the 
therapeutic armamentarium in the metastatic setting is still based on a chemotherapy backbone 
with either an anti-VEGF agent without the aid of predictive biomarkers, or an anti-EGFR 
monoclonal antibody with the aid of RAS mutations as negative predictive biomarkers to exclude 
patients who do not benefit from such treatment. In the salvage setting after failure of previous 
therapies, the use of the multikinase inhibitor regorafenib or of the novel antimetabolite 
trifluridine-tipiracil is not driven by predictive biomarkers, and therapy with inhibitors of the 
immune checkpoint confines its efficacy to MMR deficient tumors. The amplification of HER2 and 
rare oncogenic translocations of ALK, ROS1, or NTRK1-3 are to be considered emerging targets [1, 
2], but these as a whole account for <5% of cases and should be considered pharmacological 
targets only in RAS WT tumors[2], leaving out the substantial fraction (>50%) of RAS mutated CRCs 
as a paramount unmet clinical need.  
In this scenario, i.e. the absence of directly actionable molecular alterations in the clear majority of 
patients, several research efforts have been focused on strategies that exploit the so-called 
“susceptibility context” of individual CRC tumors. One of these clinical research fields has included 
the use of alkylating agents such as temozolomide in tumors with a reduced activity of the enzyme 
O
6
-methylguanine-DNA methyltransferase (MGMT) due to epigenetic silencing of the MGMT 
gene[3]. The latter abnormality makes tumors more vulnerable to the specific DNA damage 
exerted by these drugs.  Interestingly, several common RAS mutations (associated with G:A 
transitions) occur more frequently in cancers harboring MGMT deficiency, thus suggesting a role 
for such therapeutic strategy in this setting [4]. Clinical  application of this paradigm has provided 
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variable results, overall showing objective response rates of 3-16% and progression-free survival of 
about 2 months with TMZ monotherapy in the advanced setting [5–9]. These data, although 
sounding promising in the context of the therapeutic landscape of chemorefractory CRC, at the 
same time can be regarded as disappointing because they have been achieved under the auspices 
of precision oncology in a totally molecularly selected population. Moreover, data have been 
provided that in CRC changes in MGMT status can occur over time, making testing on archival 
tumor samples an unreliable indicator of MGMT at the actual moment of starting treatment with 
TMZ [6]. Efforts have been made by investigators involved in this clinical research field for further 
improving molecular selection by considering IHC together with digital PCR quantification of the 
lack of MGMT activity [10], and application and validation of newer more comprehensive scoring 
methodologies may lead to more unequivocal evidence of clinical benefit. 
All in all, data and consequently guidelines do not support at present time the use of TMZ based 
on MGMT methylation, and in the current issue of Annals of Oncology, the study by Morano et al. 
[11] capitalizes on their previous results [7, 8, 10] attempting  to elaborate a therapeutic strategy 
that would integrate TMZ in the therapeutic toolbox for mCRC. To this aim, Authors adopted a 
TEMIRI regimen in which bi-weekly irinotecan has been added to a classic schedule of TMZ based 
on previous studies in miscellaneous, mainly SNC and pediatric, solid tumors. They chose the 
chemorefractory setting (≥2 previous lines) and, most importantly, they elected to enroll only 
patients retaining sensitivity to irinotecan as demonstrated by a documented response or stable 
disease from the last irinotecan-based regimen and a non-progression under treatment or within 3 
months from last administration (i.e. interruption of irinotecan-based therapy for reasons other 
than progression). Under these circumstances, the primary endpoint of objective response rate 
(ORR) was established, considering the unsatisfactory 10% of TMZ alone as benchmark, and the 
study has been declared positive by achieving an ORR of 24% by TEMIRI in this setting. 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy223/5044274
by Salvatore Siena
on 25 June 2018
3 
 
The interpretation of these data is two-faceted. From a clinical standpoint, Authors must be 
congratulated for the potential plasticity that this treatment regimen would add to the 
therapeutic algorithm of mCRC: they propose to opportunistically include in selected patients after 
2
nd
 line an original molecular context of susceptibility-based enhanced chemo re-introduction. This 
could adapt to situations where patients come from an irinotecan-based therapeutic break and 
there is the need of obtaining some more ORR than expected with standard re-introduction or 
complete change in line of treatment. As a drawback, as admitted by Authors themselves, this 
strategy can be applied only to the case of treatment holidays or maintenance with adequate 
irinotecan-free interval, in an overall context that is limited to few patients and supported by a low 
level of evidence. Finally, the present TEMIRI regimen was quite well tolerated with only 16% 
patients showing ≥grade 3 adverse events and no treatment-related deaths.  
From a molecular and methodological point of view, however, this study does not clarify if and 
how much the addition of irinotecan truly enhances the antitumor effect of TMZ in this population 
selected for MGMT deficiency. If on one hand a synergistic effect of the two drugs is hypothesized 
based on the indirect assumption that topoisomerase II inhibitors may enhance efficacy of TMZ, 
on the other hand there are no preclinical data in cellular models or PDX provided, and this 
together with the design of the study - that selects only patients still sensitive to irinotecan -  does 
not allow to discriminate the extent of irinotecan contribution to the observed results and 
whether a synergistic rather than additive effect does actually take place.  
The path of precision oncology in CRC is proving increasingly complex, and the landscape of 
putative actionable molecular alterations, besides a handful of biomarkers heralding oncogene 
addiction [1] or mutational load-driven immunotherapy, is giving inconstant results [12, 13]. In this 
context, all efforts for improving therapeutic results based on molecular biomarkers, especially 
among RAS mutated cancers, should be encouraged. In CRC, methylation of MGMT proved to be a 
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necessary but not sufficient condition for achieving with TMZ the magnitude of benefit expected 
by a tailored use of this drug. The current trial of Morano et al., with the boost of irinotecan re-
introduction, leveraged this strategy to enhanced results. Whether this might represent a plateau 
of efficacy will be determined through more preclinical work and further improvement in 
molecular selection. 
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